LANDSCAPE is a single-arm phase II and multicentre trial conducted in 2013, in which the efficacy of lapatinib combined with capecitabine was demonstrated in HER2+ BC patients who had not undergone prior treatment with WBRT, capecitabine, or lapatinib. The gene discussed is ERBB2; the disease is breast cancer.